After Care


Elite Surgical understands that making the decision to have any cosmetic surgery isn’t taken lightly and that’s why our Aftercare programme promises to be with you every step of the way. Our highly experienced lead plastic surgeon and Medical Director, Mr Sultan Hassan is committed to giving you access to a member of our clinical team 24/7 which proves just how committed we are to ensuring any concerns or questions you have will be answered quickly.

Unlimited post-op appointments with a member of our nursing clinical team – whenever you need them until fully healed.
Additional days stay in hospital where needed free of charge in the event of an unexpected clinical issue.
Additional drugs and dressings supplied at no extra cost (excludes additional pressure support garments)
Access to emergency hospital telephone support (numbers supplied at discharge) which you can use at any time during your recovery or even up to 12 months later.

Up to 3 routine follow-up outpatient or virtual appointments with your consultant are included as part of your 12 month fixed care package. Out of aftercare appointments are chargeable.

Useful regulatory bodies on breast implants
The Medicines and Healthcare products Regulatory Agency (MHRA)

Make sure you have accurate and complete information before deciding to have surgery because every medical intervention carries some risk.We have produced a booklet that you may find useful. It includes a list of questions to ask before having surgery: Information for women considering breast implants
Types of breast implants
Breast implants consist of a filler material inside a silicone elastomer shell. The shell can be either smooth or textured. Some are covered with a polyurethane foam coating. Only two types of breast implant filler are currently in use in the UK:

  • silicone gel
  • saline.
  • Silicone

Silicone gel breast implants were first introduced in around 1962, when there were no specific statutory regulations in place to control the marketing and use of medical devices in the UK, the rest of Europe, or in the USA. Since then, the use of breast implants has increased gradually and it is now estimated that over 10,000 people receive breast implants each year in the UK, 80% of these opting for silicone gel-filled implants. Department of Health policy on the supply of breast implants is based on the principle of evidence based medicine and, where appropriate, reflects conclusions drawn by groups of independent experts. Currently only breast implants filled with silicone or saline are available for use in the UK.

PIP breast implants are a brand of silicone gel filled breast implants that were available in the UK until March 2010. For further information see our page on PIP breast implants.


Saline-filled breast implants consist of a silicone elastomer shell, which is filled with saline solution (salt water). There are no restrictions on the sale or use of CE-marked saline-filled breast implants in the UK.

Polyurethane coated implants

Polyurethane-coated silicone gel breast implants are now available for implantation in the UK. These implants consist of a silicone elastomer shell filled with silicone gel. The shell is coated with a polyurethane foam which breaks down over time. Polyurethane-coated breast implants were removed from the UK market in 1991, following concerns about the possible carcinogenic risk from the polyurethane breakdown product.

The Committee on Carcinogenicity* concluded that carcinogenic risk from these implants is small and unquantifiable. In April 2005, the manufacturer of one type of polyurethane-coated breast implant reintroduced them to the UK. The manufacturer claims that the incidence of capsular contracture is lower than with other types of breast implant, and that the movement or rotation is less. In April 2005, the MHRA issued a letter to the plastic surgery professional bodies file to bring this issue to their attention and to inform them of the risks and claimed benefits.

*The Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC) provides expert advice to the Chief Medical Officer and UK Government Departments.

The following types of implant are not available in the UK:

  • hydrogel-filled
  • soya bean oil-filled (Trilucent™)
  • implants with a titanium coating.


This type of implant consisted of a silicone elastomer shell containing hydrogel filler. Hydrogels are polymeric materials that have the ability to swell in water without dissolving and retain water within their structures.

Until December 2000, there were two models of hydrogel filled breast implants on the UK market – PIP Hydrogel and NovaGold. Because of continuing concern over the safety of breast implants, the Medical Devices Agency (a forerunner to the MHRA) carried out a series of investigations into the safety of the various filler materials used in the implants available in the UK. The agency’s investigations into hydrogel-filled breast implants revealed inadequacies in the manufacturers’ biological safety assessments and concluded that there was not enough information to fully assess the safety of either of the hydrogel filler materials. When they were made aware of the results of these reviews, both manufacturers decided to withdraw their hydrogel-filled breast implants from the UK market in December 2000 as a precautionary measure, pending further studies to establish the safety of the filler materials. The Medical Devices Agency issued two alerts at the time: DA 2000(07) – Breast Implants: PIP Hydrogel and DA 2000(08) – Breast Implants: NovaGold.

It must be emphasised that no definite risk has been identified. The concern lay only with the way the safety of the hydrogel fillers had been assessed. The MHRA is continuing to monitor the safety of these implants and, based on the currently available evidence, does not recommend that women with hydrogel-filled breast implants have them removed unless they are experiencing problems. Women who think that they may have hydrogel breast implants and are concerned, should contact the surgeon who carried out their operation. Clinicians and members of the public should continue to report adverse incidents to the MHRA.

Soya bean oil (Trilucent™)

These implants were removed from the market in 1999, and in 2000 the Medical Devices Agency (a forerunner to the MHRA) recommended that these implants should be explanted. A clinical research programme was sponsored by AIE Inc and was carried out by an independent panel of experts to investigate the long-term health effects of Trilucent implants. This was completed in 2004. The report (Multicentre Clinical Study to Assess the Potential Risk of Exposure to Lipid Peroxidation Products in Soya Bean Oil from Trilucent Breast Implants concluded that there is no evidence for local or systemic disease risk once the implants have been removed. The MHRA issued an alert (MDA/2004/047) in September 2004 to notify interested parties of the conclusions of this study and of the closure of the Trilucent Care Centre (TCC), which had been set up for patients with these implants. The MHRA continues to record and investigate reports of adverse events associated with Trilucent breast implants. If further problems are identified, we will issue advice.

Background information

Trilucent breast implants were on sale throughout the EU between 1995 and March 1999. They consisted of a silicone elastomer shell with a lipid filler based on soyabean oil. Since they were first marketed in 1995 over 9,000 implants were sold in the UK, and implanted into almost 5,000 women. As a result of an investigation into reports of inflammation associated with rupture of Trilucent breast implants, the Medical Devices Agency reviewed the manufacturer’s safety assessment. This revealed serious concerns relating to the long term safety of the breast implants, in particular in relation to the breakdown of the lipid filler. As a result of the agency’s concerns the company voluntarily withdrew the product from the market in March 1999 and the Medical Devices Agency issued Advice Notice AN 1999(01). The withdrawal was a precautionary measure until further information could be gathered about the biological safety and clinical experience with these implants. The advice given at that time was that there was no evidence to suggest that removal of Trilucent breast implants was indicated but that women should be advised to seek an immediate consultation if they noticed unusual breast swelling or inflammation associated with their Trilucent breast implants.

The first results of further analytical studies on the filling material in Trilucent breast implants became available in May 2000. The Medical Devices Agency convened a group of independent experts (the Trilucent Advisory Group) to consider the available scientific evidence. This group made an assessment of the risk to women with these implants and provided advice to the Medical Devices Agency. A statement(25KB) summarising the Trilucent Advisory Group’s conclusions and advice is available, with the minutes of a meeting(33Kb) held on 19 May 2000. Based on this advice, the Medical Devices Agency issued Hazard Notice HN 2000(05). In 2000, a programme of research was initiated to investigate the risks to women implanted with Trilucent breast implants. This programme was directed, on behalf of AEI Inc, by a panel of independent experts. The programme was completed in 2004. The panel concluded that:

the recommendation that Trilucent breast implants should be removed remains appropriate because exposure of local tissue to toxic compounds has been confirmed
there is no evidence for local or systemic disease risk once the implants have been removed
no further studies are needed to assess the potential risk of Trilucent breast implants.
This information was the subject of MHRA Medical Device Alert MDA/2004/047.
Further to the completion of the research programme, the manufacturer agreed to provide the MHRA with six-monthly reports of adverse incidents involving Trilucent breast implants until 2009. The MHRA has reviewed the manufacturer’s reports and reports received from other sources over the period 1999-2009 and has seen:

no evidence of cancer or increased risk of cancer or reproductive toxicity
a decrease in the number of reports received annually since 2006.

The MHRA continues to record and investigate reports of adverse events associated with Trilucent breast implants. If further problems are identified, the MHRA will issue advice.

Titanium coated

These implants are made from a silicone gel filler with a titanium coated silicone elastomer shell. The only model of titanium-coated breast implant known to have been CE marked was the TiBREEZE implant manufactured by GfE Medizintechnik GmbH in Germany. These implants were filled with silicone gel material manufactured by Poly Implant Prothese (PIP).

TiBREEZE implants were recalled from the EU market in 2004. All but four of the implants supplied to the UK were returned to the manufacturer and therefore might have been implanted into UK patients.

Adverse events

If safety concerns arise with any breast implants, the MHRA will investigate and issue advice to the health service if necessary.

Patients, members of the public and healthcare professionals can report problems with breast implants directly to us via our website.
We also have some guidance on reporting:

Report a safety problem with a medical device

incident reporting in general breast implants – key reportable adverse events
Manufacturers of breast implants should be aware of the following document:

Guidance on the medical devices vigilance system for CE marked breast implants